SLC13A3 and liver cancer: In mouse cells, β-catenin-activated liver cancer cells undergo autophagic ferroptosis and GSH depletion when SLC13A3 is silenced [93], which indicates that SLC13A3 may be a useful therapeutic target for the treatment of human liver tumors containing GOF CTNNB1 mutations.